Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer-Reference-Cited by-同舟云学术

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

Published:2021-12-15 Issue: Volume: Page:candisc.1265.2020
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Chang Chewei Anderson,Jen Jayu^ORCID,Jiang Shaowen,Sayad Azin,Mer Arvind Singh^ORCID,Brown Kevin R^ORCID,Nixon Allison M.L^ORCID,Dhabaria Avantika,Tang Kwan Ho^ORCID,Venet David^ORCID,Sotiriou Christos^ORCID,Deng Jiehui^ORCID,Wong Kwok-Kin,Adams Sylvia,Meyn Peter,Heguy Adriana,Skok Jane A^ORCID,Tsirigos Aristotelis^ORCID,Ueberheide Beatrix,Moffat Jason^ORCID,Singh Abhyudai,Haibe-Kains Benjamin^ORCID,Khodadadi-Jamayran Alireza^ORCID,Neel Benjamin G

Funder

Foundation for the National Institutes of Health

HHS | NIH | NCI | Basic Research Laboratory

Government of Ontario

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug tolerance and persistence in bacteria, fungi and cancer cells: Role of non-genetic heterogeneity;Translational Oncology;2024-11

2. Trehalose catalytic shift is an intrinsic factor in Mycobacterium tuberculosis that enhances phenotypic heterogeneity and multidrug resistance;2024-09-13

3. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

4. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

5. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14